Nsclc Treatment Raw Material Ldk378 Powder CAS 1032900-25-6 Ceritinib

Introduction:
Ceritinib is a drug for the treatment of lung cancer. It is an ALK inhibitor. It was approved in April 2014 by the Food and Drug Administration for the treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) following treatment with crizotinib.

Function:
1.It is a tyrosine kinase inhibitor of anaplastic lymphoma kinase (ALK). It can promote the development of cancer cells by blocking the protein and inhibit the cells expressing EML4-ALK and NPM-ALK fusion protein.
2.Cerinib, a novel ALK inhibitor, is highly active in advanced patients.